Decoy Therapeutics
DCOY
4 hedge funds and large institutions have $10.5K invested in Decoy Therapeutics in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 5 closing their positions.
0.19% more ownership
Funds ownership: 0.11% → 0.3% (+0.19%)
43% less funds holding
Funds holding: 7 → 4 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
80% less capital invested
Capital invested by funds: $51.4K → $10.5K (-$40.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.17K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$353 |
| 4 |
Morgan Stanley
New York
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$18.2K |
| 2 |
SG
StoneX Group
New York
|
-$13K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$7.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.08K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$23 |
DCOY Hedge Fund Activity: Q1 2026 in Review
4 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2026, worth a combined $10.5K — down 80% from $51.4K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DCOY and 2 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $5.6K. The largest seller was Warberg Asset Management, exiting entirely with an estimated $18.2K sold.
- 4 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2026, down from 7 in Q4 2025.
- Funds reported $10.5K of Decoy Therapeutics stock for Q1 2026, down 80% quarter-over-quarter.
- 2 funds opened new Decoy Therapeutics positions in Q1 2026 and 5 closed out, a net change of -3 holders.
- The largest Decoy Therapeutics buyer in Q1 2026 was Tower Research Capital (TRC), an estimated $5.6K added.
- The largest Decoy Therapeutics seller in Q1 2026 was Warberg Asset Management, an estimated $18.2K sold.
Based on aggregated 13F filings for Q1 2026.